Dados B3Stocks › BLAU3 PT

Saúde

BLAU3 — BLAU FARMACÊUTICA S.A.

CNPJ 58.430.828/0001-60 · listed classes: BLAU3 · CVM code 24627

10.2P/E
1.3P/B
7.0EV/EBITDA
-4.3%FCF yield
13.3%ROE 2025
12.2%ROIC 2025
P/E, P/B and EV/EBITDA priced at the session of 2026-05-14 (R$ 10.10), the first one after the 2025 filing became public on 2026-05-14 — point-in-time, not the 31 December price. acoes_ajustadas_por_evento

The full history, year by year

The arrow opens the path from the figure down to the line in the regulator's file. A cell with ! carries a caveat; a dash is a withheld figure — hover for the reason. Nothing is hidden.

indicator201720182019202020212022202320242025
ROE 74.5%!68.2%81.9%104.4%35.0%21.0%13.1%10.4%13.3%
ROIC 49.8%!49.7%58.5%51.7%34.4%27.0%13.2%10.9%12.2%
ROA 28.2%!25.7%30.1%25.3%18.0%14.9%8.9%6.6%8.4%
Gross margin 45.4%43.2%44.0%47.0%48.7%47.5%35.7%37.5%40.1%
EBIT margin 26.6%26.0%30.8%32.9%33.4%32.1%24.0%18.7%20.8%
Net margin 16.7%15.8%20.5%21.5%23.7%25.6%18.0%12.2%17.4%
Revenue growth (1y) 26.6%25.0%20.9%15.6%3.0%-2.4%27.8%-3.0%
Revenue growth (5y CAGR) 17.9%11.9%12.4%7.6%
Net debt/EBITDA 0.52x0.53x0.38x1.17x-1.15x-0.70x0.55x0.17x-0.04x
Current ratio 1.11x2.48x1.91x2.20x4.95x4.52x4.63x3.12x2.47x

The current year, quarter by quarter

As the company filed it in its interim report. The fourth quarter does not exist on its own in that filing — the closed year comes in the annual one, and we do not derive a Q4, so that a figure we computed never sits beside the figures the company reported. Filed on is the date the report became public, and the price is taken from it.

quarterrevenueprofitnet marginP/E TTMP/Bfiled on
2024T1359.739.711.0%8.30.982024-05-09
2024T2465.147.610.2%10.91.152024-08-26
2024T3473.669.214.6%16.11.442024-11-06
2025T1373.090.724.3%9.11.102025-05-06
2025T2464.863.213.6%7.60.952025-08-06
2025T3475.2105.522.2%7.20.972025-11-04
2026T1435.036.38.3%10.01.062026-05-07
2026T2486.655.511.4%8.20.822026-08-11

Full series, every quarter: GET /empresas/BLAU3/trimestres

Dividends per year

yearper sharepayments
2026R$ 0.15152
2025R$ 1.02435
2024R$ 0.36434
2023R$ 0.42234
2022R$ 0.84975
2021R$ 0.24813

Piotroski F-Score 5/9 (2025) — what each criterion means.

Restated filings for this company

The regulator overwrites the old version; we keep both. Figures in R$ millions: first filing on the left, restatement on the right.

fiscal yearaccountfirst filingrestated
2024DRE 3.05328.8361.2
2024DRE 3.07291.9324.3
2024DRE 3.09213.5245.9
2024DRE 3.11213.5245.9
2017BPA 1.01.0113.29.2
2017BPA 1.01.020.04.0
2024DFC_MI 6.01507.2503.3
2020DFC_MI 6.01153.7150.7

This company appears in

Other companies in Healthcare

15 more with a page, same CVM sector — a classification of the regulator's, not ours.

Take this into your code

Everything on this page is also JSON: GET /empresas/BLAU3/indicadores. WEGE3 is open for testing without a key; for the rest, create a free key (200 calls/day, no card).

Price coverage: 1,345 sessions, 2021-04-19 → 2026-09-04 · methodology · how we verify

Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 11:12 UTC. If this does not match /saude, you are reading a cached copy.